Anderson, Bryan D.

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first‐in‐class transforming growth factor‐β receptor type I inhibitor

Yingling, J. M., McMillen, W. T., Yan, L., Huang, H., Sawyer, J. S., Graff, J., Clawson, D. K., Britt, K. S., Anderson, B. D., Beight, D. W., et al. (2018) · Oncotarget

TGF-β signaling in diseasesMechanisms of cancer metastasis

Cited by 187

Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity

Campbell, R. M., Anderson, B. D., Brooks, N. A., Brooks, H. B., Chan, E. M., De Dios, A., Gilmour, R., Graff, J. R., Jambrina, E., Mader, M., et al. (2014) · Molecular Cancer Therapeutics

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 121